LEADER 04628nam 22007455 450 001 9910736993803321 005 20251008145159.0 010 $a9783031351556 010 $a303135155X 024 7 $a10.1007/978-3-031-35155-6 035 $a(MiAaPQ)EBC30679955 035 $a(Au-PeEL)EBL30679955 035 $a(DE-He213)978-3-031-35155-6 035 $a(OCoLC) 1393308349 035 $a(PPN)272274119 035 $a(CKB)27942483200041 035 $a(OCoLC)1393308349 035 $a(EXLCZ)9927942483200041 100 $a20230808d2023 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPlant-Based Therapeutics, Volume 1 $eCannabis sativa /$fby Ivan A. Ross 205 $a1st ed. 2023. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2023. 215 $a1 online resource (670 pages) 311 08$aPrint version: Ross, Ivan A. Plant-Based Therapeutics, Volume 1 Cham : Springer International Publishing AG,c2023 9783031351549 327 $aChapter 1 The History of Cannabis -- Chapter 2 The Bioactive Components of Plants -- Chapter 3 Chemical Constituents of Cannabis -- Chapter 4 The Bioactive Components of Cannabis -- Chapter 5 Neurological Effects of Cannabis -- Chapter 6 Psychotropic Effects of Cannabis -- Chapter 7 The Analgesic effects of Cannabis -- Chapter 8 Cannabis and Perinatal Development -- Chapter 9 Cannabis and Multiple Sclerosis -- Chapter 10 Cannabis and Cancer -- Chapter 11 Cannabis and Parkinson?s disease -- Chapter 12 Cannabis and the Skin -- Chapter 13 Antiviral Activities of Cannabis -- Chapter 14 Alkaline Phosphatase Stimulation. 330 $aBy examining historical applications of the compounds found in plants, this five-volume series serves as a reference for quality assurance, research, product development, and regulatory guidance of the compounds found in plant-based medicines. This work supports the growing consumers' interest in herbal medicine for wellness and health. Plant-Based Therapeutics, Volume 1: Cannabis sativa, the first in the series, covers a unique plant species and provides the framework to integrate its evidence-based scientific discoveries with healthcare therapies. Cannabis has been used in religious ceremonies and medical purposes for thousands of years. Cannabidiol (CBD), the main non-psychoactive component of Cannabis, was isolated in the 1940s, and its structure was established in the 1960s. In 1964 tetrahydrocannabinol (THC), the psychoactive component, was isolated. Cannabis has more than 500 components, of which 104 cannabinoids have been identified. Two of them, THC and CBD, have been the primary components of scientific investigations. They were approved by the FDA for chemotherapy-induced nausea and vomiting in 1985; for appetite stimulation in wasting conditions, such as AIDS, in 1992, and in 2018 for treating two forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. Beyond the indications for which cannabinoids are FDA-approved, the evidence reveals that cannabinoid receptors are present throughout the body, embedded in cell membranes, and are believed to be more numerous than any other receptor system. When cannabinoid receptors are stimulated, a variety of physiologic processes ensue. Thus, other constituents of Cannabis are extremely promising either as individual compounds or their potential synergistic or entourage effects in the treatment of numerous medical conditions. . 606 $aBotany 606 $aAlternative medicine 606 $aPharmacology 606 $aPharmaceutical chemistry 606 $aPhysiology 606 $aAgriculture 606 $aPlant Science 606 $aComplementary and Alternative Medicine 606 $aPharmacology 606 $aMedicinal Chemistry 606 $aPhysiology 606 $aAgriculture 615 0$aBotany. 615 0$aAlternative medicine. 615 0$aPharmacology. 615 0$aPharmaceutical chemistry. 615 0$aPhysiology. 615 0$aAgriculture. 615 14$aPlant Science. 615 24$aComplementary and Alternative Medicine. 615 24$aPharmacology. 615 24$aMedicinal Chemistry. 615 24$aPhysiology. 615 24$aAgriculture. 676 $a615.7827 676 $a615.7827 700 $aRoss$b Ivan A$0556495 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910736993803321 996 $aPlant-Based Therapeutics, Volume 1$94450691 997 $aUNINA